Primrose syndrome is a rare autosomal dominant condition caused by heterozygous missense variants within ZBTB20. Through an exome sequencing approach (as part of the Deciphering Developmental Disorders [DDD] study) we have identified five unrelated individuals with previously unreported, de novo ZBTB20 pathogenic missense variants. All five missense variants targeted the C2H2 zinc finger domains. This genotype-up approach has allowed further refinement of the Primrose syndrome phenotype. Major characteristics (>90% individuals) include an intellectual disability (most frequently in the moderate range), a recognizable facial appearance and brain MRI abnormalities, particularly abnormalities of the corpus callosum. Other frequent clinical associations (in 50-90% individuals) include sensorineural hearing loss (83%), hypotonia (78%), cryptorchidism in males (75%), macrocephaly (72%), behavioral issues (56%), and dysplastic/hypoplastic nails (57%). Based upon these clinical data we discuss our current management of patients with Primrose syndrome.
| INTRODUCTION
Primrose syndrome (OMIM 259050), first described in 1982 by David Primrose, has previously been associated with a moderate to severe intellectual disability, a recognizable facial appearance with deep set eyes, narrow, often down-slanting palpebral fissures, ptosis, depressed nasal bridge, and macrocephaly with or without tall stature (Alby et al., 2018; Battisti et al., 2002; Carvalho & Speck-Martins, 2011; Casertano et al., 2017; Collacott, O'Malley, & Young, 2008; Cordeddu et al., 2014; Dalal, Leslie, Lindor, Gilbert, & Espay, 2010; Lindor, Hoffman, & Primrose, 1996; Mathijssen, Van Hasselt-Van Der Velde, & Hennekam, 2006; Mattioli et al., 2016; Posmyk, Le sniewicz, Chorazy, & Wołczy nski, 2011; Primrose, 2008; Stellacci et al., 2018) . Additional reported clinical features include muscle wasting, calcified pinnae, hearing loss, cataracts, hypothyroidism (Dalal et al., 2010; Mattioli et al., 2016) , torus palatinus (a benign osseous elevation usually found on the midline of the hard palate; Collacott et al., 2008; Dalal et al., 2010; Mathijssen et al., 2006; Primrose, 2008) , and sparse body and facial hair (Battisti et al., 2002; Carvalho & Speck-Martins, 2011; Collacott et al., 2008; Lindor et al., 1996; Mathijssen et al., 2006; Primrose, 2008) .
In 2014, heterozygous pathogenic variants within ZBTB20 were shown to cause Primrose syndrome (Cordeddu et al., 2014) . ZBTB20, located at chromosome position 3q13.31, encodes one of a family of POK (POZ [pox virus and zinc finger] and Kruppel) proteins which acts as a transcriptional repressor and has a role in glucose metabolism, postnatal growth and neurogenesis (Sutherland et al., 2009; Xie et al., 2010; Zhang et al., 2012) . ZBTB20 has five C2H2 zinc finger domains To date, 14 of 15 Primrose syndrome reported ZBTB20 pathogenic variants are missense variants clustering within the first (three variants), second (six variants) and third (two variants) zinc finger domains and the linker region between the first two motifs (three variants, Figure 1a , Supporting Information Table S1 ; Mattioli et al., 2016; Casertano et al., 2017; Stellacci et al., 2018; Cordeddu et al., 2014; Alby et al., 2018) . Functional assays have supported a dominant negative mechanism of disease whereby missense variants result in a stable but dysfunctional protein with defective DNA binding (Cordeddu et al., 2014) . In contrast, haploinsufficiency of ZBTB20 causing the 3q13.31 microdeletion syndrome (OMIM 615433), has been reported to cause a similar but distinct condition also characterized by increased growth but without many of the Primrose syndrome clinical associations including the recognizable facial appearance, calcified pinnae and muscle wasting (Molin et al., 2012; Shuvarikov et al., 2013 ).
Here we report five patients with de novo ZBTB20 pathogenic missense variants, identified through trio-based exome sequencing.
This genotype-up approach has replicated the previous finding that ZBTB20 missense variants target the zinc finger domains and has allowed a nonbiased refinement of the Primrose syndrome phenotype.
| METHODS
The study was approved by the UK Research Ethics Committee (10/H0305/83), granted by the Cambridge South Research Ethics Committee. Informed consent was obtained from all families. Seven patients with de novo ZBTB20 variants were identified through the Deciphering Developmental Disorders (DDD) Study using a trio-based exome sequencing strategy and methods as previously described (Firth et al., 2009) . Five patients had missense variants, predicted to be pathogenic according to American College of Medical Genetics and Genomics (ACMG criteria PS2, PM1, PM2, PP2 and PP3; Richards et al., 2015) with evidence detailed in Supporting Information Table S2 .
These five missense variants targeted the first, second, and third zinc fingers (ZNFI, ZNFII, and ZNFIII). None had previously been reported.
The remaining two patients with de novo ZBTB20 variants were not included in the current study: one patient with a c.505G>C; p. Clinical data for the five patients with the single de novo pathogenic missense ZBTB20 variants were obtained through face to face review by one of the authors, all experienced dysmorphologists, and a standardized proforma. Growth parameter z scores were calculated with reference to the Centers for Disease Control and Prevention (CDC) data other than BMI z scores where we calculated z scores with reference to World Health Organization (WHO) data (Freeman et al, 1995) . Photographs, with accompanying consent to publish, were received from all five families.
| RESULTS
Clinical details are summarized in Table 1 Dentition was poor with delayed secondary dentition. A brain MRI scan was unremarkable and bone age was delayed (the bone age was 2 years at chronological age of 3 years 4 months). 
Hypoplastic corpus callosum
Abbreviations: +, present; −, absent; BHC, birth head circumference; BMI, body mass index; BW, birth weight; DM, diabetes mellitus; GTT, abnormal glucose tolerance; HC, head circumference; Ht height; na, not applicable; nk, not known; SD, standard deviations; Wt, weight.
| DISCUSSION
Through an exome sequencing approach, the current study has identified five patients with novel single de novo ZBTB20 missense variants. These data replicate previous reports that Primrose syndrome missense variants cluster within the zinc finger domains and expand the clustering to include the third zinc finger domain where only two pathogenic variants had previously been reported (Alby et al., 2018; Stellacci et al., 2018) . Stellachi et al., recently reported a frameshift variant outside of the zinc finger domains said to cause Primrose syndrome. Given the findings both from the current study and previously reported studies, a frameshift variant would be an unusual cause of Primrose syndrome. In addition, further evaluation of the phenotype in this patient suggests greater similarity with the 3q13.31 microdeletion syndrome than Primrose syndrome with increased growth and a milder intellectual disability than that normally described in Primrose syndrome. In addition, this patient, facially, bears a significant resemblance to the patient reported by Rasmussen et al. (2014) , with a 3q13.31 microdeletion, rather than patients with Primrose syndrome. and dysplastic or hypoplastic nails (8/14, 57%). In addition, distal muscle wasting, abnormalities of glucose metabolism, contractures and ectopic calcification of the pinnae were reported in at least 80% of adult patients. None of these four clinical features were reported in the five patients in the current study. However, our oldest patient was only 13.4 years and so it is possible that our five patients may still develop these. Of interest, given that abnormalities of glucose metabolism are associated in older individuals with Primrose syndrome and the association between abnormalities of glucose metabolism and increased BMI, the BMI was ≥2SD in two of the three individuals older than 10 years and for whom data were available. In contrast, in the seven individuals younger than 10 years for whom data were available, only one had a BMI ≥2SD.
Based on our findings and data from the 14 previously reported patients with missense variants, our practice is to ensure appropriate learning and behavior support is in place and to refer to physiotherapy for management of hypotonia and/or contractures. We undertake a hearing evaluation for all our patients. In addition, until there are longitudinal data, we are screening our patients for both abnormalities of glucose metabolism and thyroid abnormalities.
All five variants in the current study occurred de novo. One variant was mosaic. This has implications for the counseling of families with regard to recurrence risk. We would counsel a 1% recurrence risk where a child has a de novo constitutive variant, with no evidence of mosaicism, reflecting the possibility of germline mosaicism and we would offer prenatal testing in future pregnancies. In contrast, the risk of recurrence of a de novo mosaic variant is very low (background rate) and invasive prenatal testing for future pregnancies would not be recommended.
Although the current study has allowed further refinement of the Primrose syndrome phenotype, the total number of patients and, in particular, the number of adults with Primrose syndrome remains small. However, as exome/genome sequencing becomes more accessible, it is likely that additional individuals, of all ages, will be identified with Primrose syndrome. This will result in an improving understanding of the Primrose syndrome phenotype, a greater knowledge of the long term syndrome complications and the implementation of optimal, consistent, evidence-based management.
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